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Abstract
Purpose Cerebral neoplasms of various histological origins may show comparable appearances on conventional Magnetic
Resonance Imaging (MRI). Vessel size imaging (VSI) is an MRI technique that enables noninvasive assessment of mi-
crovasculature by providing quantitative estimates of microvessel size and density. In this study, we evaluated the potential
of VSI to differentiate between brain tumor types based on their microvascular morphology.
Methods Using a clinical 3T MRI scanner, VSI was performed on 25 patients with cerebral neoplasms, 10 with glioblas-
toma multiforme (GBM), 8 with primary CNS lymphoma (PCNSL) and 7 with cerebral lung cancer metastasis (MLC).
Following the postprocessing of VSI maps, mean vessel diameter (vessel size index, vsi) and microvessel density (Q) were
compared across tumors, peritumoral areas, and healthy tissues.
Results The MLC tumors have larger and less dense microvasculature compared to PCNSLs in terms of vsi and Q
(p= 0.0004 and p< 0.0001, respectively). GBM tumors have higher yet non-significantly different vsi values than PCNSLs
(p= 0.065) and non-significant differences in Q. No statistically significant differences in vsi or Q were present between
GBMs and MLCs. GBM tumor volume was positively correlated with vsi (r= 0.502, p= 0.0017) and negatively correlated
with Q (r= –0.531, p= 0.0007).
Conclusion Conventional MRI parameters are helpful in differentiating between PCNSLs, GBMs, and MLCs. Additionally
incorporating VSI parameters into the diagnostic protocol could help in further differentiating between PCNSLs and
metastases and potentially between PCNSLs and GBMs. Future studies in larger patient cohorts are required to establish
diagnostic cut-off values for VSI.
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Introduction
Vessel size imaging (VSI) is a magnetic resonance imag-
ing (MRI) technique that allows in vivo examination of
cerebral microvascular morphology by providing quantita-
tive estimates of mean vessel diameter and density within
a given voxel [1–3]. The MR-VSI is based on exploiting
the ratio of relaxation rate changes (Δ R*2/ΔR2) measured
by gradient echo (GE) and spin echo (SE) pulse sequences
in vascular networks during the passage of an intravascular
contrast agent [1, 4]. The T2*-weighted and T2-weighted
images generated from GE and SE during dynamic suscep-
tibility contrast (DSC) perfusion imaging are sensitive to
large vessels and microvasculature <10μm in diameter, re-
spectively [4]. Thus, VSI combines two different contrasts
that are sensitive to a specific range of vessel sizes each.
Troprès et al. [5] showed that VSI enables a clear dif-
ferentiation of intratumoral, peritumoral, and healthy con-
tralateral tissue in an animal model of glioma. Further work
by Kiselev et al. [3] demonstrated the feasibility of us-
ing this technique in studying human tumors by generat-
ing quantitative measures of the average microvessel di-
ameter (vessel size index, vsi) using the apparent diffu-
sion coefficient (ADC) obtained from an additional diffu-
sion-weighted MRI scan, relative cerebral blood volume
(rCBV), and mean microvessel density (Q). Several ani-
mal studies thereafter employed MR-VSI in assessing the
vascular development of various tumors, including brain tu-
mors [2, 5, 6], subcutaneously induced solid tumors [7–9]
as well as monitoring vascular remodeling during thera-
peutic interventions [7, 9, 10]. Moreover, several clinical
studies demonstrated the reliability and feasibility of this
technique in providing quantitative estimates of the patho-
logical changes in the microvascular networks of brain tu-
mors [3, 11] and ischemic stroke [12, 13].
Several validation studies, both preclinical and clinical,
depicted a high correlation between the microvascular mea-
sures obtained by VSI and those obtained by histopathol-
ogy [14–17]. The VSI also proved useful in differentiating
glioma subtypes and predicting tumor grades [15, 17, 18].
In addition, a technique similar to VSI yet with more ad-
vanced postprocessing has been used in isolated studies
of monitoring vascular responses in tumor patients receiv-
ing antiangiogenic treatment with promising results [19];
however, the potential utility of VSI in differentiating be-
tween cerebral neoplasms of different etiologies based on
the quantitative properties of their microvasculature has not
yet been investigated.
Different tumor types can elicit entirely different pat-
terns of vascularization [20, 21]. We hypothesized that mi-
crovessel diameter and microvessel density values assessed
by VSI will be different enough across different types of
malignant cerebral neoplasms to assist in their differen-
tial diagnosis. If successful, this method could provide new
MRI-based biomarkers for the preoperative differentiation
of various intracerebral neoplasms.
Material andMethods
Study Design
This project is part of an ongoing proof of concept study
(MINC: vessel size imaging as a novel MRI method for
assessing microvasculature in neurological conditions) car-
ried out at the Neuroradiology Group of the Center for
Stroke Research Berlin (CSB). The local ethics committee
of the Charité Universitätsmedizin Berlin (Campus Ben-
jamin Franklin) approved the study (#EA4/131/19).
Patients
Our cohort consisted of 25 patients (11 females, 14 males)
with a median age of 71 years (range 40–87 years). Pa-
tients of this pilot study were enrolled over a period of
10 months (between November 2019 and July 2020). In-
cluded were patients who presented with pathological in-
tracerebral masses and from whom written consent was ob-
tained. Excluded were patients with poor image quality in-
troduced due to motion artifacts preventing reliable image
analysis. Our cohort consisted of 10 patients with a WHO
grade IV glioblastoma multiforme (GBM), 8 patients with
primary central nervous system lymphomas (PCNSL) and
7 patients with metastases of lung cancer (MLC). The di-
agnosis was confirmed by histopathology in all cases. All
patients gave written informed consent for the experimental
protocol. Of the patients, 19 were scanned prior to any treat-
ment whereas 6 patients had received either chemotherapy
or radiotherapy 1 year to a few days prior to the MRI scan.
Patients who received treatment within the last 6 months
before scanning were later excluded from a subanalysis of
our study (n= 5).
Magnetic Resonance Imaging (MRI) Acquisition
All measurements were performed using a clinical 3T Pris-
mafit MRI scanner (Siemens Healthineers; Erlangen, Ger-
many) with a 64-channel head coil. The VSI was performed
using repeated single-shot gradient echo (GE) spin echo
(SE) echo planar readouts during the intravascular passage
of a paramagnetic contrast agent bolus (10ml Gadovist®
1.0mmol/ml, Bayer AG, Leverkusen, Germany) at a flow
rate of 5ml/s was followed by a bolus of 30ml isotonic
saline flush. Two versions of the VSI sequence were
used (standard sequence with TR= 2000ms, TE= 18ms
and 84ms for GE and SE, respectively, flip angle 90º
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and an alternative protocol with TR= 2100ms, TE= 18ms
and 92ms, respectively) because technical problems oc-
casionally arose (in 7 patients) necessitating the replace-
ment of the standard protocol. The voxel resolution was
1.8× 1.8× 5.5mm3 with a total of 16 slices and full supra-
tentorial brain coverage for both protocols. Parameters of
the VSI sequence are adapted from [15] using single-band
excitation, which has a comparable signal-to-noise ratio to
the multiband method [22].
In total, 50 dynamic volumes were acquired during
contrast administration. Additional acquired sequences in
the examination were: diffusion-weighted imaging (DWI),
fluid-attenuated inversion recovery (FLAIR), and a con-
trast-enhanced 3D T1-weighted high-resolution magnetiza-
tion-prepared rapid acquisition gradient echo (MPRAGE)
sequence.
Data Processing
The dynamic susceptibility measurements were processed
similar to [15] with the following procedure: first, the
change in relaxation rates for both GE and SE were cal-
culated using the proportionality to log(S(t)/S0), where S0
denotes the baseline signal, calculated as average over the
first 5 timepoints of the time series. Then, a T1 leakage
correction was performed [11]. From this, the first bolus
passage was extracted with the procedure described in [23].














R2 and ΔR2 represent the changes in the relaxation
rates for GE and SE acquisitions due to the administra-
tion of contrast agent, respectively, d is the mean vessel
diameter calculated in μm, rCBV is the cerebral blood
volume fraction normalized to a global average of 3.2%
and ADC is the apparent diffusion coefficient. Exploit-
ing Eq 1, a fit to the measured datapoints of R2
2=3
and ΔR2 was performed with a linear Deming regression,
which correctly accounts for errors on both axes. From
the fitted regression coefficient, the mean vessel diame-
ter d was calculated. From the same linear fit, the mean
vessel density Q as given in Eq 2 and defined in [24] was
calculated.
Only timepoints during the bolus passage were used for
curve fitting by setting a threshold to the measured time
series, R2 and ΔR2. Furthermore, a threshold of 200μm
was applied to mean vessel diameter maps to exclude (null)
voxels, which were beyond the limits of the mathematical
model.
Perfusion maps of relative cerebral blood volume (rCBV)
and relative cerebral blood flow (rCBF) were calculated
using the VEOcore Software (VEObrain GmbH, Freiburg,
Germany) [24] based on the gradient echo images from the
VSI scans. The rCBV was calculated as the integral over
the ΔR2 after leakage correction and first bolus extraction
and rCBF was determined using a deconcolution with an
arterial input function. All image processing and annotation
were performed using MATLAB-based scripts imbedded
into a local installation of the NORA imaging platform
(www.nora-imaging.org).
Delineation of Regions of Interest (ROIs)
Blinded to vsi and Q maps, regions of interest were man-
ually delineated by A.F. (master’s student) and validated
by I.G. (neuroradiologist with 10 years experience) on the
high-resolution contrast-enhanced T1-weighted images, or
on T2-weighted FLAIR images in the case of a non-en-
hancing tumor. Only one PCNSL patient had non-enhanc-
ing tumor lesions with discrete areas of T2-hyperintensity,
representing a clear progress of the tumor based on a com-
parison with a recent imaging time point.
Fig. 1 Manual selection of the regions of interest (ROIs) on postcon-
trast T1-weighted images. a tumor (yellow), b peritumoral area (green),
c healthy gray matter from both thalami (orange), and d healthy white
matter from the centrum semiovale (blue)
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For each patient, at least 4ROIs were obtained for eval-
uation (Fig. 1):
1. The whole tumor, obtained by delineating the contrast-
enhancing segment of the tumor and taking care to ex-
clude necrotic areas (if present) (Fig. 1a),
2. Peritumoral areas, obtained by expanding the original tu-
mor ROI by 4 voxels along each axis, then subtracting
the original tumor ROI from the dilated one (Fig. 1b),
3. Healthy gray matter tissue (GM) collected from both tha-
lami (Fig. 1c), and
4. Healthy white matter (WM) obtained mainly from the
centrum semiovale (Fig. 1d).
In cases where multiple neoplastic lesions existed, each
of them was separately delineated and treated as a distinct
tumor. Only tumor lesions ≥0.1ml in volume were included
in the analysis, as smaller tumors might deliver imprecise
results due to noise and partial volume effects. The VSI and
Fig. 2 VSI maps shown using
the NORA medical imag-
ing platform in patients with
a glioblastoma multiforme,
b primary CNS lymphoma,
c metastatic lung cancer.
Left: post-contrast T1-weighted
images showing enhancement of
tumor regions. Middle: corre-
sponding mean vessel diameter
(vsi) maps. Right: corresponding
microvessel density (Q) maps.
Tumor regions show elevated
mean vessel diameters with
decreased microvessel densities
compared to healthy tissues
perfusion maps were registered to the T1-weighted images.
All defined ROIs were then superimposed on VSI and per-
fusion maps for the quantitative estimation of median vsi
in μm, median Q in s–1/3, relative cerebral blood volume
(rCBV) and cerebral blood flow (rCBF) (percentage rela-
tive to the contralateral hemisphere).
Statistical Analysis
The study involved 25 patients in total with 3 different
types of brain tumors and different numbers of lesions per
patient. Here, a patient is considered as a single cluster and
the lesions per patient as dependent replicates. Since the
sample sizes are rather small, inferring any distributional
assumptions of the data (e.g., normality and/or variance
homoscedasticity) would be questionable. Therefore, we
analyzed the data using a purely nonparametric approach
for dependent replicates proposed by [36].
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Note that although the test statistics derived in [36] are
applicable for two independent samples with replicated ob-
servations, we have modified its test procedure to take three
independent groups of this study into account. Furthermore,
we consider the weighted scheme described in [36] as the
size of each cluster is rather different. Comparisons be-
tween healthy tissues of GM andWMwere performed using
Welch’s t-test or Mann-Whitney test, depending on the nor-
mality of data. The level of significance was set to 5% and
multiple comparisons were adjusted for using Bonferroni
correction. The statistical analyses were performed using
R version 4.0.3 (https://www.r-project.org/).
Results
VSI Maps of the Different Brain Tumor Types
Fig. 2 depicts examples of the resultant mean vessel diame-
ter (vsi) and microvessel density (Q) maps of patients with
different tumor etiologies.
Mean Vessel Diameter (vsi) and Microvessel
Density (Q) Values.
Table 1 summarizes the median and interquartile range
(IQR) values of vsi and Q in tumors, peritumoral areas,
and healthy tissues. We compared the microvessel diam-
eter and microvessel density values across three different
tumor types: glioblastoma multiforme (GBM; Ncases = 10,
Nlesions = 37), primary CNS lymphomas (PCNSL; Ncases = 8,
Nlesions = 30), and metastatic lung cancer (MLC; Ncases = 7,
Nlesions = 31).
The MLC showed significantly larger microvessel size
diameters compared to PCNSL, (p= 0.0004). GBM had
larger vsi values than PCNSL, however, this difference did
not reach statistical significance (p= 0.065). No significant
Table 1 Summary of median and interquartile range (IQR) values of vsi and Q in tumors, peritumoral areas, and healthy tissues
Diagnosis GBM PCNSL MLC Healthy GM Healthy WM
Vessel size index (vsi)



































GBM glioblastoma multiforme, PCNSL primary CNS lymphoma, MLC metastatic lung cancer, GM gray matter, WM white matter
difference in vsi was found between MLC and GBM tu-
mors (p= 0.971). Regarding the measure of microvessel
density (Q), only PCNSL tumors showed denser microves-
sels compared to MLCs (p< 0.0001) but no significant
difference was found between GBM and PCNSL tumors
(p= 0.942) or between GBM and MLC tumors (p= 0.119).
In peritumoral areas the only significant difference was
in vessel sizes between MLC and PCNSL (p= 0.0005)
where the former showed larger vessel sizes than the latter.
Healthy GM tissues showed both significantly larger and
denser microvasculature than healthy WM (p= 0.0015 and
p= 0.022, respectively). Boxplot representations of the dis-
tribution of vsi and Q values across tissue types are shown
in Fig. 3. All tumor lesions, regardless of the tumor type,
showed significantly larger microvessel sizes and lower
microvessel densities in comparison to healthy tissues.
Generally, vsi was highest and Q lowest within the tumor
lesions, followed by peritumoral areas and lastly healthy
tissues of gray and white matters (p< 0.005 for all). Results
remained unchanged in a subanalysis of only those tumor
lesions that were either naïve to treatment or were not
subject to any treatment for the past 6 months (30/37 GBM
lesions, 19/30 PCNSL lesions, and 28/31 MLC lesions).
Perfusion and Diffusion Parameters.
Cerebral blood volume (CBV) and cerebral blood flow
(CBF) expressed in % relative to the contralateral hemi-
sphere, as well as apparent diffusion coefficient (ADC) val-
ues were also calculated and compared between tumors and
healthy tissues (see Table 2).
The GBM tumors and the peritumoral areas showed
significantly higher CBV than PCNSLs (p= 0.0001 and
p= 0.0003, respectively). GBM tumors also had signifi-
cantly higher CBF values compared to PCNSL (p= 0.0488)
whereas the peritumoral areas had higher yet not signif-
icantly different CBF values (p= 0.08). Moreover, GBM
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Fig. 3 Boxplot representation of vessel size index (vsi) (a) and microvessel density (Q) (b) in different tumor types, their surrounding ar-
eas, and healthy gray and white matters. Whiskers indicate 5–95 percentiles. GBM glioblastoma multiforme, PCNSL primary CNS lym-
phoma, MLC metastatic lung cancer, GM gray matter, WM white matter
tumors and their peritumoral areas showed significantly
higher CBV (p= 0.035 and p= 0.037) and CBF values
(p= 0.023 and p= 0.030) compared to the corresponding
areas of MLC. No significant difference in either perfusion
parameter was found between MLC and PCNSLs.
Regarding diffusivity, ADC values were significantly
higher in MLC tumors than in both GBM (p= 0.001) and
PCNSL (p= 0.005). Similarly, the peritumoral areas had
significantly higher ADC values when compared to ei-
ther GBM (p= 0.001) or PCNSL (p= 0.0001). ADC values
were found non-significant between tumors and peritumoral
areas of GBM vs. PCNSL (p> 0.05).
Correlation of VSI Parameters with Tumor Volumes.
Spearman correlation coefficient was computed to assess
the relationship between tumor size and the characteris-
tics of its supplying microvasculature. Out of the 98 tumor
lesions in our sample 79 lesions were included in the anal-
ysis (37 GBM, 30 PCNSL and 12 MLC) with 19 lesions
excluded due to necrotic cores with viable tissue only at the
edges since their ROIs would not be representative of the
actual tumor volume.
Separated into groups based on tumor type, there was
a significant positive correlation between GBM tumor
volume and microvessel sizes (r= 0.502, p= 0.0018) and
a significant negative correlation with microvessel den-
sity (Q) (r= –0.531, p= 0.0007). This indicates that in-
creases in tumor size are correlated with larger yet less
dense microvasculature (Fig. 4). No significant correlation
was found for PCNSLs and MLCs.
Equally, no significant correlations were found between
tumor volumes and any of the perfusion or diffusion pa-
rameters (Supplementary Table 1).
Discussion
Accurate differential diagnosis of malignant cerebral neo-
plasms using conventional MRI techniques remains chal-
lenging in everyday practice. In the brain, glioblastoma
multiforme (GBMs), primary CNS lymphomas (PCNSLs),
and metastases belong to the most frequently encountered
malignancies. All of them also show comparable appear-
ances on conventional MRI sequences as solitary or multi-
focal, strongly enhancing, non-calcified, soft tissue masses
surrounded by edema. The purpose of this study was to
evaluate the usefulness of an MRI technique, vessel size
imaging (VSI), in the preoperative differentiation of these
tumors. In our study, we focused on comparing tumors and
their surrounding areas, since both compartments provide
important pathophysiological information necessary for tu-
mor identification.
Our results showed that tumor microvasculature of MLC
had significantly larger microvessel diameters compared to
PCNSLs, whereas microvessel size did not significantly
differ between MLC tumors and GBMs nor between
PCNSLs and GBMs. A histopathological study by Gi
et al. demonstrated that metastatic brain tumors, similar
K
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Table 2 Summary of median and interquartile range (IQR) values of CBV, CBF, and ADC in tumors, peritumoral areas, and healthy tissues
GBM PCNSL MLC Healthy GM Healthy WM
Cerebral blood volume (CBV)
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GBM Glioblastoma multiforme, PCNSL Primary CNS Lymphoma, MLCMetastatic Lung Cancer, GM gray matter, WM white matter
to high-grade gliomas, are characterized by a large, thick,
dilated glomeruloid microvasculature compared to normal
brain tissue or malignant lymphomas [26], which could
explain the non-significant difference in the mean vessel
diameters between GBMs and MLCs. The lack of statisti-
cal significance in the comparison of microvessel size and
density between GMBs and PCNSLs could be attributed
to the small sample size but partially also to the fact that
GBMs seem to alter their microvasculature as they evolve,
with smaller tumors presenting with smaller vessels more
similar to PCNSLs (which are less vascular and exhibit
a characteristic angiocentric pattern in which tumor cells
accumulate densely within and around blood vessels [27]).
All peritumoral areas showed microvessel diameters that
were significantly smaller than the corresponding tumors
yet significantly larger than normal brain tissues. A similar,
yet inverse, gradient was revealed for the parameter Q, both
possibly indicating a gradual metamorphosis of one tissue
type to the other.
Histologically, and in contrast to GBMs and metastatic
tumors, PCNSLs lack abundant neovascularization and tu-
mor angiogenesis which matches our results of denser mi-
crovascular networks with smaller vessel caliber and lower
rCBV. Our results are in line with several perfusion stud-
ies [28–30], which found that PCNSLs have lower perfu-
sion than high-grade gliomas attributed to their different
vascularity. VSI can therefore serve as a complementary
method to aid the precise differentiation between MLC and
PCNSL entities where perfusion parameters fail. The tu-
mors and peritumoral areas of GBMs showed significantly
higher perfusion (rCBV and rCBF) compared to those of
MLCs which could be attributed to the highly infiltrative na-
ture of glioblastomas as opposed to metastases, which are
surrounded by pure vasogenic edema that leads to a local
compression of microcirculation [31]. Indeed, several stud-
ies showed that peritumoral rCBV has a high diagnostic
accuracy in discriminating between GBMs and metastases,
where the former showed significantly higher values than
the latter [30, 32, 33].
In contrast to standard perfusion, in GBMs VSI detected
a correlation between tumor volume and the values of vsi
and Q. Hence, smaller GBM tumors could have vessel sizes
that are comparable to those of PCNLS but start resembling
MLCs with more enlarged vessels as they gain size during
their malignant progression. Comparing differently sized
GBM tumors to PCNSLs and MLCs might be of interest to
follow up in future studies with larger patient cohorts.
Estimation of vsi and Q in GBMs using the same VSI
sequence has been previously reported by Kellner et al.
[15], where they showed median (IQR) values of 74.5μm
(59.25–81.25) and 0.305s–1/3 (0.29–0.387), respectively.
These results were not significantly different from ours
(p= 0.397 and p= 0.286, respectively). This consistency
could further substantiate the reliability of VSI as a method
to estimate microvascular characteristics. Indeed, several
clinical studies showed that vessel sizes of high-grade
gliomas obtained by VSI significantly correlated with
those estimated by histopathology [16, 25]; however, it is
important to note that these estimated vsi values do not nec-
essarily accurately reflect actual microvascular anatomy.
This is due to a known inherent systematic error of the
method which leads to overestimation of normal vessel
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Fig. 4 Scatterplot representation of the correlation analysis between tumor volumes and VSI parameters within glioblastoma multiforme (GBM)
tumors. a Vessel size index (vsi) shows a relatively strong positive linear relationship with tumor volume (r= 0.502, n= 37, p= 0.0017). b Mi-
crovessel density (Q) shows a relatively strong negative correlation with tumor volume (r= –0.531, n= 37, p= 0.0007). Error bars indicate 95%
CI. Note: various types of noise (image acquisition, co-registration, partial volume effect, etc.) may contribute to a certain variability in the final
datapoints in the figure. This is particularly true for lesions with very small volume
sizes and underestimation of grossly enlarged vessels [2,
15].
Classical MRI techniques, such as DWI and DSC perfu-
sion-weighted imaging are already widely applied in diag-
nostic imaging of intracranial tumors, and several previous
studies have shown differences in perfusion and diffusion
values between GBMs, PCNSLs, and/or metastases [28, 30,
34, 35]. Standard DSC utilizes GE contrast only whereas
VSI utilizes both dynamic GE and SE. As previously men-
tioned, GE is sensitive to vessels of all sizes while SE is
weighted toward microvascular structures <10μm in diam-
eter [4]. Therefore, while VSI as a technique incorporates
conventional DSC imaging, it is also able to provide addi-
tional insight into the properties of microvasculature, which
are often concealed in pure GE measurements, predomi-
nated by large vessels. Moreover, as VSI is designed to
deliver quantitative parameters, it also enables intersubject
comparison. The VSI sequence implemented on our clin-
ical MRI scanner possesses identical spatial resolution in
comparable scan time and contrast agent dosage to stan-
dard DSC MRI and can therefore be used interchangeably
and feasibly as part of a routine diagnostic work-up for pa-
tients with suspected intracranial neoplasms. Considering
that our department is primarily devoted to cerebrovascular
diseases, a general limitation of our study is the small sam-
ple size of only 25 randomly selected brain tumor patients
and the heterogeneous composition of the cohort with tu-
mors of different treatment status. Another limitation is the
inclusion of a patient with few non-enhancing lesions as
well as the assessment of several lesions in a single case
as distinct tumors; however, this was compensated by using
a novel yet scientifically validated statistical method.
Current developments in the field involve a technique
called vessel architectural imaging (VAI), which can ex-
tract, through advanced post-processing, even more infor-
mation about the microvascular structures (such as the pre-
dominance of venules or arterioles in a voxel) using the
same sequence as VSI [19, 22]. Building upon VAI, there
is an opportunity to gain even deeper insights into the com-
plexity and heterogeneity of vascular changes in cerebral
neoplasms. In conclusion, this is the first study to evalu-
ate the potential of VSI in differentiating between different
etiologies of cerebral neoplasms and our findings support
the utilization of VSI as an add-on to conventional MRI to
facilitate tumor differentiation.
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